申请人:Rhone-Poulenc Rorer Limited
公开号:US06124343A1
公开(公告)日:2000-09-26
This invention is directed to compounds of formula I ##STR1## wherein R.sup.1 is CN, CH.sub.2 CN, CH.dbd.CHCN, CHO, or CH.dbd.CHCO.sub.2 H; R.sup.2 is aryl lower alkoxy, heteroaryl lower alkoxy, aryl lower alkylthio or heteroaryl lower alkylthio wherein each of the aryl and heteroaryl moieties is optionally substituted; R.sup.3 is halogen; R.sup.4 is optionally substituted aryl or optionally substituted heteroaryl; R.sup.5 is carboxy or an acid isostere; X is oxygen or sulphur; and n is zero or 1; or an N-oxide thereof, prodrug thereof solvate thereof, or pharmaceutically acceptable salt thereof, which compounds have endothelin antagonist activity. The invention is also directed to methods for preparing the compounds of formula I and their pharmaceutical use.
这项发明涉及式I的化合物##STR1##其中R.sup.1为CN、CH.sub.2CN、CH.dbd.CHCN、CHO或CH.dbd.CHCO.sub.2H;R.sup.2为芳基低烷氧基、杂芳基低烷氧基、芳基低烷硫基或杂芳基低烷硫基,其中芳基和杂芳基中的每一个可选择地被取代;R.sup.3为卤素;R.sup.4为可选择地被取代的芳基或可选择地被取代的杂芳基;R.sup.5为羧基或酸异构体;X为氧或硫;n为零或1;或其N-氧化物、前药、溶剂化合物或药学上可接受的盐,这些化合物具有内皮素拮抗活性。该发明还涉及制备式I化合物及其药用的方法。